 Drug Industry
"Drug Industry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
| Descriptor ID |
D004345
|
| MeSH Number(s) |
J01.576.655.750
|
| Concept/Terms |
Drug Industry- Drug Industry
- Industry, Pharmaceutic
- Industries, Pharmaceutic
- Pharmaceutic Industries
- Pharmaceutic Industry
- Industry, Drug
- Drug Industries
- Industries, Drug
- Industry, Pharmaceutical
- Industries, Pharmaceutical
- Pharmaceutical Industries
- Pharmaceutical Industry
|
Below are MeSH descriptors whose meaning is more general than "Drug Industry".
Below are MeSH descriptors whose meaning is more specific than "Drug Industry".
This graph shows the total number of publications written about "Drug Industry" by people in this website by year, and whether "Drug Industry" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 | | 2008 | 1 | 1 | 2 | | 2010 | 0 | 2 | 2 | | 2011 | 2 | 0 | 2 | | 2012 | 2 | 1 | 3 | | 2013 | 2 | 1 | 3 | | 2015 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Industry" by people in Profiles.
-
Vukovic S, McAdam L, Zlotnik-Shaul R, Amin R. Putting our best foot forward: Clinical, treatment-based and ethical considerations of nusinersen therapy in Canada for spinal muscular atrophy. J Paediatr Child Health. 2019 Jan; 55(1):18-24.
-
Luzzatto L, Hollak CE, Cox TM, Schieppati A, Licht C, Kääriäinen H, Merlini G, Schaefer F, Simoens S, Pani L, Garattini S, Remuzzi G. Rare diseases and effective treatments: are we delivering? Lancet. 2015 Feb 28; 385(9970):750-2.
-
Holbrook A, Lexchin J, Pullenayegum E, Campbell C, Marlow B, Troyan S, Weijer C, Blackmer J, Brazil K, Willison D. What do Canadians think about physician-pharmaceutical industry interactions? Health Policy. 2013 Oct; 112(3):255-63.
-
Eckermann S, Willan AR. Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing. Pharmacoeconomics. 2013 May; 31(5):393-401.
-
Estey MP, Cohen AH, Colantonio DA, Chan MK, Marvasti TB, Randell E, Delvin E, Cousineau J, Grey V, Greenway D, Meng QH, Jung B, Bhuiyan J, Seccombe D, Adeli K. CLSI-based transference of the CALIPER database of pediatric reference intervals from Abbott to Beckman, Ortho, Roche and Siemens Clinical Chemistry Assays: direct validation using reference samples from the CALIPER cohort. Clin Biochem. 2013 Sep; 46(13-14):1197-219.
-
Chen MH, Willan AR. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods. Clin Trials. 2013 Feb; 10(1):54-62.
-
Ungar WJ. Understanding the value of information from pediatric clinical research. Paediatr Drugs. 2012 Oct 01; 14(5):295-7.
-
Willan AR, Eckermann S. Value of information and pricing new healthcare interventions. Pharmacoeconomics. 2012 Jun 01; 30(6):447-59.
-
MacDonald NE, MacLeod S, Stanbrook MB, Hébert PC, Flegel K, Rosenfield D. No regulatory double standard for natural health products. CMAJ. 2011 Dec 13; 183(18):2079.
-
Peterson B, Hébert PC, MacDonald N, Rosenfield D, Stanbrook MB, Flegel K. Industry's neglect of prescribing information for children. CMAJ. 2011 Jun 14; 183(9):994-5.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|